Left bundle branch pacing vs biventricular pacing in heart failure patients undergoing cardiac resynchronization therapy: an updated systematic review and meta-analysis.

Expert Rev Med DevicesAug 3, 2026 (epub)
Clinical ResearchCardiology

Muhammad Asad Jahangir, Ahmad Hassan, Affaf Mahmood et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of left bundle branch pacing (LBBP) versus biventricular pacing (BVP) in 9,278 heart failure patients undergoing cardiac resynchronization therapy. LBBP was associated with a significant reduction in all-cause mortality (OR 0.57) and heart failure hospitalization (OR 0.50), while also improving CRT response and LVEF.

Key findings

  • LBBP reduced fluoroscopy time by 7.00 minutes compared to BVP.
  • LBBP lowered all-cause mortality with an odds ratio of 0.57.
  • LBBP improved left ventricular ejection fraction (LVEF) by 3.58%.
  • LBBP enhanced CRT response with an odds ratio of 1.85.

Why it matters

The findings suggest that LBBP may offer better clinical outcomes than BVP for heart failure patients receiving CRT, potentially influencing treatment decisions and improving patient management strategies.

Source

PubMed · PMID 42524756

Published in Expert Rev Med Devices. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.